PT-141

Activate Central Libido & Arousal Pathways

PT-141, also known as Bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist. It is widely researched for its ability to influence sexual desire and arousal by targeting neural pathways in the central nervous system rather than peripheral vascular mechanisms.

Because PT-141 operates independently of nitric oxide and blood-flow modulation, it has become a compound of interest in research focused on libido signaling, sexual motivation, mood, and neurobehavioral pathways in both male and female models.

Product features

• Synthetic melanocortin receptor agonist — studied for CNS-driven libido signaling.
• Lyophilized (freeze-dried) formulation — ensures long-term stability and compound integrity.
• Sterile 3 mL glass vial — designed for research-grade handling.
• Butyl rubber stopper — supports secure multi-access resealing.
• ETO-sterilized & depyrogenated — finished with tamper-evident aluminum flip-top.

Key benefits (Research Highlights)

• Sexual desire & arousal signaling — studied for enhancing libido and sexual motivation in both male and female research models.
• Non-vascular mechanism — acts through neural melanocortin pathways rather than nitric oxide or blood-flow systems.
• Female libido research — investigated in studies related to hypoactive sexual desire disorder (HSDD).
• Rapid signaling onset — research environments report CNS activity within hours, with extended signaling duration.
• Mood & motivation interest — melanocortin pathways are linked to emotional processing, confidence, and reward signaling.
• Emerging neuroprotective research — under investigation for broader CNS health and appetite-related signaling.

Research reference: dosage ranges used in studies

Scientific literature evaluating PT-141 has explored controlled exposure models to assess neural response, libido signaling duration, and receptor sensitivity. These studies often examine onset timing, persistence of effects, and CNS tolerability.

All referenced quantities and schedules are provided strictly for educational and informational context within controlled research environments.
They do not represent usage instructions or recommendations.

Research reference: safety & tolerability observations

Across controlled clinical and observational research settings, PT-141 has demonstrated a generally acceptable tolerability profile. Reported observations vary depending on exposure rate, individual sensitivity, and study design.

• Transient nausea or flushing reported during early exposure phases
• Temporary headache or fatigue observed in some research participants
• Localized tissue responses noted in peptide administration models

All safety-related information is derived from published research and observational findings and is presented solely for transparency within a scientific context.

Not sure which libido-focused peptide fits your research? Our consultation service can help determine whether PT-141 aligns with your performance, sexual health, or mood-related research goals.

Disclaimer: For research purposes only. Not intended for human consumption. Information provided is for educational reference and does not constitute medical advice.